Theacrine alleviates inflammation and lung injury in septic mice by mediating SIRT3

Qitai Song, Yao Liu, Ye Tian*
Department of Emergency, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province 646000, China

*For correspondence: Email: yitian8077@163.com; Tel: +86-0830-3165854

Sent for review: 6 July 2023 Revised accepted: 30 October 2023

Abstract

Purpose: To evaluate the effect of theacrine on sepsis progression and sepsis-induced lung injury and its mechanism of action.

Methods: Lung injury model of lipopolysaccharide (LPS)-induced sepsis was made in the mice by injected with 3 mg/kg LPS dissolved in 50 μL PBS or only PBS (control group = 10). The remaining three groups (divided into ten mice per group) were administered theacrine (10, 20, and 40 mg/kg), by oral gavage 1 hour after LPS treatment. Hematoxylin and eosin (H&E) staining was performed to confirm the effect of theacrine on lung injury. Quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA) were conducted to determine inflammatory and oxidative stress factors. TUNEL as well as immunoblot assays were carried to confirm its effect on apoptosis and mechanism of action.

Results: Theacrine significantly improved lung injury as well as lung relief score in LPS-induced sepsis mice (p < 0.01) and it significantly reversed the increased levels of inflammatory cytokines in a dose-dependent manner in LPS-induced sepsis mice (p < 0.01). In addition, theacrine administration significantly reduced the increased intensity of ROS and MDA levels, and significantly improved the levels of SOD in lung tissues (p < 0.01). Furthermore, it improved LPS-induced apoptosis of lung tissue cells and alleviated lung injury by significantly activating SIRT3 pathway (p < 0.01).

Conclusion: Theacrine alleviates inflammation and lung injury in septic mice by mediating SIRT3, thereby making it a potential lead in the development of drugs against sepsis-related inflammation and lung injury.

Keywords: Sepsis, Lung injury, Theacrine, LPS, Oxidative stress, SIRT3 pathway

INTRODUCTION

Sepsis is defined as an organ dysfunction caused by an aberration in the host’s response to infection [1]. Nearly 30% of patients with sepsis develop multiple organ dysfunction syndrome. The lungs are one of the most vulnerable organs to sepsis [2]. Lipopolysaccharide (LPS) could induce acute inflammation by stimulating host cells to produce inflammatory cytokines and also induce acute lung injury (ALI) by recruiting activated neutrophils as well as macrophages into the lungs [3,4]. Drug therapy is very important for the treatment of sepsis patients and to improve the therapeutic effect, there is a need
to develop a large number of effective therapeutic drugs to improve the cure rate [5-7].

SIRT3 is an NAD-dependent deacetylase mainly confined to the mitochondria and its deficiency is related to the regulation of mitochondrial function and redox homeostasis [8]. Previously, it has been reported that expression of SIRT3 is reduced in LPS-induced acute lung injury and SIRT3 deficiency also aggravates LPS-induced inflammation and ROS production, making acute lung injury more serious [9]. So far, studies have shown that multiple drugs target SIRT3 and significantly improve the treatment effect of sepsis. *Camellia assamica* var *kucha* is a unique plant, mainly distributed in provinces of China [10]. Theacrine (1,3,7,9-tetramethylxuric acid), one of the major alkaloids found in *Camellia assamica* var *kucha*, is a purine alkaloid associated with bioactive functions such as anti-depressant, sedative, hypnotic and lipid metabolism regulation [11,12]. In addition, it has anti-inflammatory and antioxidant effects as it has been shown to reduce inflammation, and oxidative stress and improve liver damage [13,14]. Furthermore, studies have revealed that Theacrine activates SIRT3 [14]. However, the role and mechanism of Theacrine in sepsis-induced lung injury remain unclear. This study aims to investigate the effect of Theacrine in a sepsis model and to elucidate its potential as a drug for the treatment of sepsis.

**EXPERIMENTAL**

**Animals**

Male C57BL/6 mice (40) were obtained from Shanghai Laboratory Animal Center (Shanghai, China). The experiment was approved by the Ethics Committee of Southwest Medical University (approval no. Ky2018029). Animals were handled in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines [15]. Mice were injected with 3 mg/kg LPS (Sigma, USA) dissolved in 50 μL PBS or only sterile PBS (control group = 10). The remaining three groups (divided into ten mice per group) were administered theacrine (10, 20, or 40 mg/kg), (purchased from Sigma) by oral gavage 1 hour after LPS treatment.

**Histological analysis**

The lungs of mice were recovered after sacrificing the mice. Lung tissues were fixed with 5 % PFA, then embedded with paraffin and cut into slices. The sections were counterstained with hematoxylin-eosin staining (H&E). Lung injury score was determined by considering hemorrhage and alveolar wall thickness. Staining degree was quantified as follows: 0, 1, 2, 3 and 4 representing no staining, mild staining, moderate staining, severe staining and very severe staining, respectively.

**Quantitative polymerase chain reaction (qPCR)**

Total RNA was isolated from lung tissues using RNA purification Kit (Tiangen, Beijing, China) and reverse transcribed to generate cDNA according to the manufacturer’s specifications. The primers are listed in Table 1.

**Enzyme-linked immunosorbent assay (ELISA)**

The IL-1β, TNF-α, IL-6, MDA, and SOD levels were assayed by ELISA kit (Abcam, UK). Samples were aspirated into wells and biotin-conjugated primary antibodies (1:1000) were added into the wells before the addition of avidin-conjugated HRP for 2 hours at room temperature. Then, enzyme substrate was added for color development and the result was measured with a microplate reader (Varioskan LUX, Thermo, USA) at 450 nm wavelength.

**Immunofluorescence**

Lung tissues were fixed with 5 % PFA. Afterward, sections were sliced and incubated with the ROS kit or TUNEL kit (Beyotime, Beijing, China). After rinsing with PBS and counterstaining with DAPI, the images were captured under a fluorescence microscope (Carl Zeiss, Germany).

**Western blotting**

Lung tissue lysates were collected after RIPA buffer addition. Protein concentration was obtained with a BCA protein assay kit (P0010, Beyotime, China).

<table>
<thead>
<tr>
<th>Table 1: Primers used for qPCR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gene</strong></td>
</tr>
<tr>
<td>TNF-α</td>
</tr>
<tr>
<td>IL-6</td>
</tr>
<tr>
<td>IL-1β</td>
</tr>
<tr>
<td>β-actin</td>
</tr>
</tbody>
</table>

Song et al

*Trop J Pharm Res, November 2023; 22(11): 2260*
Then proteins were separated with 10% SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes. Then the membranes were incubated with 5% BSA followed by primary monoclonal antibodies including Bax (1:1000, ab32503, Abcam, UK), Cleaved caspase 3 (1:1000, ab32402, Abcam, UK) and GAPDH (1:1000, ab8245, Abcam, UK) for 2 h at room temperature. The membranes were maintained in HRP secondary antibodies for 2 h (1:2000) at room temperature and the signals were detected with ECL detection kit.

Statistical analysis

Statistical analysis was performed using GraphPad Prism software. Data are presented as mean ± standard deviation (SD). *P < 0.05 was considered statistically significant.

RESULTS

Theacrine relieves lung injury induced by LPS

The results of the histological examination of LPS-induced acute lung injury and relief score of theacrine administration are displayed in Figure 1. The mice displayed tissue injury characterized by irregular alveolar integrity. This phenotype was reversed after the administration of theacrine at a concentration of 10, 20 and 40 mg/kg. Administration of 20 and 40 mg/kg of theacrine significantly improved the lung score (*P < 0.05).

Figure 1: Histological analysis of lung tissues and injury score in control, LPS and theacrine-treated LPS mice at various concentrations. **P<0.001, LPS vs control; ***P<0.001, LPS + theacrine vs LPS

Theacrine inhibits inflammatory cytokines

The effect of theacrine on inflammatory markers in LPS-induced mice is shown in Figure 2. Administration of LPS significantly increased the levels of IL-6, IL-1β and TNF-α levels (*P < 0.05). However, theacrine significantly reversed the increased levels of these cytokines in a dose-dependent manner (*P < 0.05; Figure 2 A). Furthermore, this trend was confirmed by the results of ELISA (Figure 2 B). Therefore, theacrine inhibits the production of inflammatory cytokines in LPS-induced mice.

Figure 2: Theacrine inhibited inflammatory cytokines. (A) mRNA levels of IL-6, IL-1β and TNF-α in lung tissues of control, LPS and theacrine-treated LPS-induced mice at the indicated concentrations of theacrine; (B) Levels of IL-6, IL-1β and TNF-α in lung tissues of control, LPS and theacrine-treated LPS-induced mice at the indicated concentration of theacrine. **P<0.001, LPS vs control; $P<0.05, $$$P<0.001, LPS + theacrine vs LPS

Theacrine alleviates LPS-induced oxidative stress

The effect of Theacrine on LPS-induced oxidative stress was explored in the mice model. The levels of reactive oxygen species were determined by immunostaining experiment. LPS treatment increased the ROS levels in the lung tissues of mice (Figure 3 A). However, Theacrine treatment at a concentration of 10, 20 and 40 mg/kg reversed the increased intensity of ROS caused by LPS induction in lung tissues. Furthermore, Theacrine treatment significantly reduced the LPS-induced increase in the MDA levels and significantly improved the levels of SOD (*P < 0.05; Figure 3 B). Therefore, Theacrine alleviates LPS-induced oxidative stress in lung tissues.

Figure 3: Immunostaining for ROS and MDA levels in lung tissues of control, LPS and theacrine-treated LPS mice at various concentrations. **P<0.001, LPS vs control; $$$P<0.001, LPS + theacrine vs LPS

Theacrine improved LPS-induced apoptosis of lung tissues

The results of TUNEL assays revealed that LPS treatment induced apoptosis in lung tissues (Figure 4 A). However, Theacrine suppressed apoptosis of lung tissues caused by LPS treatment (Figure 4 A). In addition, LPS treatment increased Bax as well as cleaved caspase-3 expression in the lung tissues,
whereas Theacrine treatment suppressed apoptosis of lung tissues, with the decreased expression of Bax as well as cleaved caspase-3 (Figure 4 B). Therefore, Theacrine improved LPS-induced apoptosis of lung tissues.

The level of expression of SIRT3 protein in the lung tissues (p < 0.05). However, theacrine treatment reversed the increased SIRT3 expression caused by LPS treatment in lung tissues (Figure 5 A). The effects of theacrine-mediated lung injury were analyzed by an examination of the SIRT3 inhibitor, 3-TYP. As shown in Figure 5 B, 3-TYP stimulation increased the cytokine levels, which was suppressed by theacrine. The decreased MDA as well as SOD levels induced by theacrine was reversed by 3-TYP treatment (Figure 5 C). In addition, 3-TYP treatment induced the expression of Bax as well as cleaved caspase 3 in lung tissues, effectively reversing the effect of theacrine treatment (Figure 5 D). Taken together, theacrine alleviated lung injury by activating the SIRT3 pathway.

**DISCUSSION**

Sepsis is a clinical process of systemic inflammation caused by bacterial infection. It is a common complication in critically ill patients after surgery and is the basis for multiple organ improvement disorder syndrome. The lung is the most affected organ in multiple organ injury complicated by sepsis. Acute lung injury (ALI) appears earliest and has the highest incidence
It is a systemic inflammatory response syndrome which is caused by various internal and external pulmonary pathogenic factors [16]. In sepsis, various inflammatory factors are activated, which lead to impaired immune function and damaged lung tissues, and this promotes the occurrence and development of ALI [17]. Although there has been some progress in the clinical application of drugs to treat it, there is still a need to develop more effective therapeutic drugs.

Theacrine has been shown to possess good physiological activities such as anti-depressant, sedative and hypnotic, anti-inflammatory and analgesic properties, reduces the stress damage of liver cells and is one of the research hotspots of purine alkaloids [18]. In addition, it strengthens the heart, and diuresis, dilates coronary artery and relaxes bronchial smooth muscles [18]. Theacrine has been shown to ameliorate liver fibrosis in rats via the activation of the Sirtuin 3-farnesoid X receptor pathway [12]. Interestingly, theacrine has been reported to alleviate sepsis-induced acute kidney injury by suppressing the NLRP3/caspase-1 inflammasome [20]. In this study, an LPS-induced sepsis mice model was recruited and used to induce lung injury. Theacrine was found to improve lung injury, oxidative stress and apoptosis caused by sepsis.

Studies have shown that damage to lung tissue caused by oxidative stress plays an important role in sepsis-induced ALI. Many factors can induce the body to produce free radicals and lead to the homeostasis disorder, so that free radicals cannot be smoothly removed, resulting in lung tissue damage and ultimately leading to ALI [19]. Therefore, avoiding oxidative stress in ALI is crucial to relieving symptoms [19]. In this study, Theacrine was shown to also alleviate sepsis-induced ALI via the suppression of oxidative stress.

Previously, it was shown that SIRT3 expression is reduced in LPS-induced ALI and that SIRT3 deficiency aggravates LPS-induced inflammation and ROS production, making ALI more serious [9]. Therefore, SIRT3 could serve as a target for LPS-induced ALI. Interestingly, the result of this study shows that theacrine activates SIRT3 and improves LPS-induced lung tissue injury. However, the precise mechanism needs further study.

**CONCLUSION**

Theacrine activates SIRT3 pathway and improves LPS-induced lung injury, inflammation, oxidative stress and apoptosis in sepsis. Therefore, it can potentially be developed as a drug for the treatment of sepsis and related inflammatory responses.

**DECLARATIONS**

**Acknowledgements**

This work was supported by Sichuan Province Key Clinical Specialty construction project (Grant no. 2023GJZKP001).

**Funding**

None provided.

**Ethical approval**

None provided.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Conflict of Interest**

No conflict of interest associated with this work.

**Contribution of Authors**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Qitai Song, Yao Liu and Ye Tian designed the study and carried out the experiments, supervised the data collection, analyzed and interpreted the data, prepared the manuscript for publication and reviewed the draft of the manuscript. All authors read and approved the manuscript for publication.

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org//read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
REFERENCES